Log In
BCIQ
Print this Print this
 

PRL001

  Manage Alerts
Collapse Summary General Information
Company Perle Bioscience Inc.
DescriptionCombination of low-dose cyclosporine and omeprazole, a proton pump inhibitor (PPI)
Molecular Target Cyclophilin ; H+/K ATPase pump
Mechanism of ActionH+/K+ ATPase pump inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationDiabetes
Indication DetailsTreat Type I diabetes
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today